Health Atlas
Menu
Evidence-led reference

Mental wellbeing

Transgender health: primary care, treatment choices, fertility and age-specific evidence

11 sources · Latest source check 2026-10-20 UTC
On this page

Transgender health includes ordinary primary care and any gender-related support or treatment a person seeks. Gender diversity is not itself a mental disorder. WPATH distinguishes gender identity from gender dysphoria, the distress some people experience; individual needs and goals differ.[1]

Separate the care domains before comparing outcomes

Separate the care domains before comparing outcomes
DomainWhat it involvesBoundary
Primary and preventive careScreening based on organs, history and riskIdentity alone does not determine screening[3]
Psychosocial supportSupport for wellbeing, distress and personal goalsGender diversity is not a diagnosis by itself[1]
Gender-affirming hormonesTestosterone or feminising hormone regimensEffects and monitoring differ by treatment[2]
Puberty suppressionMedicines that suppress pubertal hormone activitySeparate adolescent evidence and access rules[8]
Surgery and voice careDistinct procedures or communication therapiesOptions depend on the person’s goals[1]

Start with the person’s goals and an understandable care plan

WPATH’s 2022 standards describe a range of social, psychological, hormonal, surgical and voice-related services. These are options within individualized care, not a compulsory sequence. Ask what a proposed intervention is intended to change, what alternatives exist and which effects may persist. Consent and aftercare matter for each intervention separately. A guideline recommendation is professional guidance rather than proof that every option produces the same outcomes.[1]

Routine screening continues alongside specialist care

UCSF recommends an ongoing medical and surgical history and organ-based cancer screening using current local criteria. A retained cervix, breast tissue or prostate can matter even when a record’s gender marker changes. Hormone exposure, surgery, age, symptoms and personal risk affect decisions. This principle does not supply a universal screening schedule, and a symptom should be evaluated rather than waiting for a routine screening invitation. Ask how records and invitations will reflect your actual needs.[3]

Discuss fertility and contraception before treatment decisions

UCSF distinguishes hormone effects on reproductive function from removal of ovaries or testes. Fertility preservation may involve sperm, eggs or embryos, depending on anatomy and development. Recovery after stopping hormones is not guaranteed, and options have costs and uncertainties. Hormones alone are not reliable contraception when sexual activity could result in pregnancy. Discuss pregnancy plans and prevention with a clinician; do not assume absent periods establish infertility or independently change prescribed treatment.[4]

Hormone treatment needs preparation and follow-up

The Endocrine Society’s 2017 guideline recommends evaluating conditions that treatment could worsen, explaining expected physical changes, and arranging clinical and laboratory monitoring. Bone health, cardiovascular risk and retained organs can require attention. Some changes are partly irreversible. Its recommendations distinguish adults, adolescents and prepubertal children; they are not a dosing guide or a statement of current legal eligibility. Ask which tests matter for your regimen, what symptoms to report and who manages follow-up if you move or change services.[2]

Adolescent services and adult services have different arrangements

NHS England’s April 2026 specification covers children and young people before their eighteenth birthday and prioritizes holistic multidisciplinary assessment and psychological support. It considers coexisting mental-health, developmental and family needs and links specialist care with local services. This is an England-specific service framework, not a universal treatment rule. Referral, consent, prescribing, funding and waiting-list arrangements vary by jurisdiction and can change. Check current official local pathways rather than importing a guideline’s age language as law.[10]

Voice care can address more than how high or low a voice sounds

Pitch means how high or low a voice sounds. Resonance concerns its tone; intonation is variation used for meaning or expression; volume is loudness. Voice and communication therapy can explore these different features in relation to a person’s own goals. The Northern Region Gender Dysphoria Service describes an initial discussion with a qualified speech and language therapist about the voice, concerns, possibilities and whether therapy is wanted. This is a local England service example, not a required transition step or a promise of the same pathway everywhere.[11]

Evidence & uncertainty

Evidence must be matched to age, intervention and outcome. A review of adolescent masculinising and feminising hormones found possible mental-health improvement but limited high-quality research. It does not justify assigning one average benefit or risk to every transgender person.[7]

Selected-source overview · Independent review pending

Published questions

Does being transgender mean I must use hormones or surgery?

Selected-source overview · Independent review pending. Read the evidence context.

No. WPATH describes different care options and individual goals. Gender identity does not require one treatment sequence, and people can discuss support without committing to a procedure.[1]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Do I still need screening after changing my gender marker?

Selected-source overview · Independent review pending. Read the evidence context.

Possibly. UCSF bases screening on retained organs, history, symptoms and current risk-based criteria. Ask how your records and screening invitations will be kept accurate.[3]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Are gender-affirming hormones contraception?

Selected-source overview · Independent review pending. Read the evidence context.

No. UCSF cautions that hormone treatment alone is unreliable contraception when pregnancy is possible. Fertility effects and fertility-preservation decisions need individualized discussion.[4]

Evidence behind this answer
  • Fertility options for transgender persons

    academic clinical guidance · 2016
    Selected original substantive page passages inspected · Introduction: hormones/gonadectomy, preservation, uncertain recovery and contraception

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Why are blood tests and follow-up needed?

Selected-source overview · Independent review pending. Read the evidence context.

Hormone effects and adverse effects vary. The Endocrine Society recommends clinical and laboratory monitoring and assessment of conditions that treatment could worsen.[2]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Does the adult testosterone trial apply to adolescents or estrogen?

Selected-source overview · Independent review pending. Read the evidence context.

No. It tested immediate testosterone against a short waiting period in selected adults seeking masculinization. Other ages, treatments and long-term outcomes require their own evidence.[5]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Did the youth cohort prove that hormones prevent suicide?

Selected-source overview · Independent review pending. Read the evidence context.

No. It was observational, outcomes varied, and two participants died by suicide. Average psychosocial improvement does not establish prevention of suicide deaths.[6]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is evidence for puberty suppression the same as evidence for hormones?

Selected-source overview · Independent review pending. Read the evidence context.

No. The reviews evaluated different interventions. Puberty-suppression research had limited high-quality evidence, uncertain psychological outcomes and important longer-term bone-health questions.[8]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is a professional guideline also the local eligibility rule?

Selected-source overview · Independent review pending. Read the evidence context.

No. England’s youth service specification is a particular current pathway. Age, referral, consent, prescribing and funding rules must be checked with the relevant official local service.[10]

Evidence behind this answer

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

Is gender-related voice therapy only about changing pitch?

Selected-source overview · Independent review pending. Read the evidence context.

No. The local NHS leaflet also describes resonance, intonation and loudness. Assessment starts with the person’s own communication concerns and goals rather than one prescribed voice.[11]

Evidence behind this answer
  • Northern Region Gender Dysphoria Service: Voice and Communication Therapy Information Leaflet

    official local service patient information · 2024
    Complete relevant original HTML and linked eight-page PDF read. Local England service used for definitions and individual goal-setting, not comparative effectiveness, universal eligibility, hormone effects, surgery availability or unsupervised voice exercises. HTML and PDF share PIC/908/0624 June 2024 V1 despite differing website publication/copyright/reference-access dates; one underlying work. · Original What do we work on, Initial appointment, individual goals and version-control footer; linked PDF pages 2–4 and 8

This answer summarizes selected sources. An independent appraisal of the complete evidence has not been completed.

A short adult testosterone trial supports a bounded benefit

Nolan and colleagues randomized 64 adults seeking testosterone in Melbourne to immediate treatment or a three-month standard waiting period. At three months, immediate treatment improved measured gender dysphoria, depression and suicidal-ideation scores. The trial was open-label, small and short; participants knew their allocation and people with specified contraindications were excluded. These results concern adults seeking masculinization and the tested regimens. They do not establish effects of estrogen, puberty suppression or surgery, long-term safety, or prevention of suicide deaths. Symptom improvement is meaningful without making those wider claims.[5]

A youth cohort describes improvement with important limits

Chen and colleagues followed 315 participants aged twelve to twenty receiving testosterone or estradiol at four US specialist centers for two years. Average appearance congruence and psychosocial measures improved, with variation between participants and groups. This was an observational cohort without a randomized untreated comparison; access to specialist support and other factors may influence outcomes. Two participants died by suicide. The study cannot establish that hormones prevent suicide or predict an individual’s course, and ongoing mental-health care remains relevant.[6]

Longer-term observational risks require interpretation

Getahun and colleagues studied 2,842 transfeminine and 2,118 transmasculine health-system members with matched comparison groups. The transfeminine cohort had higher venous-thromboembolism incidence, with differences increasing over follow-up. The authors identified limits including hormone use outside the health system and insufficient evidence for firm conclusions about transmasculine risks. An observational association is not a precise causal risk for every dose, route or current regimen. It supports discussing risk factors and monitoring rather than treating all hormones as interchangeable.[9]

Adolescent hormone evidence is still developing

Taylor and colleagues’ 2024 review included 53 studies, many using before-and-after designs. Moderate-quality evidence suggested mental-health improvement during masculinising or feminising hormone treatment, but evidence for several psychosocial, cognitive and fertility outcomes was limited. Few studies adequately controlled important differences or accompanying interventions. Improvement in a cohort and uncertainty in a wider review can coexist. The review and the youth cohort may share evidence and are not independent replications. Decisions require explicit discussion of known effects, uncertainties and follow-up.[7]

Puberty suppression has its own evidence questions

A separate 2024 review included fifty puberty-suppression studies and found limited high-quality evidence. Pubertal suppression was demonstrated, while conclusions about psychological outcomes were uncertain and bone-health concerns required attention. Subsequent hormone treatment complicates attribution of longer-term outcomes to suppression alone. Neither “fully risk-free” nor “proven ineffective for everyone” follows from these findings. Specialist assessment should explain uncertainty alongside current local access arrangements.[8]

References

  1. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8

    Professional association clinical guideline

    World Professional Association for Transgender Health; Coleman and colleagues · Content/publication date: 2022
    Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
    Cited sections: Introduction, terminology appendix, primary-care and individualized treatment-choice passages

    Professional consensus and recommendations; not independent proof of all outcome claims. Selected passages inspected, not full guideline appraisal.

  2. Gender Dysphoria/Gender Incongruence Guideline Resources

    Professional association clinical guideline summary

    Endocrine Society · Content/publication date: 2024
    Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
    Cited sections: Essential points and recommendations 1.4–1.5, 3.2–3.4, 4.1–4.6

    Page dated 25 October 2024 presents September 2017 guideline recommendations. Clinical age language is not a statement of current law; no dose prescribed.

  3. General approach to cancer screening in transgender people

    Academic clinical guidance

    Madeline B. Deutsch; University of California San Francisco · Content/publication date: 2016
    Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
    Cited sections: Organ-based screening, current criteria and updated medical/surgical history

    Dated clinical principle, not a current detailed screening schedule or claim of equal cancer risks.

  4. Fertility options for transgender persons

    Academic clinical guidance

    Paula Amato; University of California San Francisco · Content/publication date: 2016
    Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
    Cited sections: Introduction: hormones/gonadectomy, preservation, uncertain recovery and contraception

    Dated resource; no experimental technique is represented as currently standard. Used for counseling/contraception principles, not modern technique-success rates.

  5. Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial

    Randomized controlled trial

    Nolan and colleagues · Content/publication date: 2023
    Accessed: 2026-10-14 UTC · Selected original substantive page passages inspected
    Cited sections: 64 adults, 3-month open-label immediate versus standard waiting-period trial; selected exclusions, symptom outcomes and limitations

    Selected full methods/results inspected; no long-term, other-hormone, pediatric or suicide-death inference.

  6. Psychosocial Functioning in Transgender Youth after 2 Years of Hormones

    Prospective observational cohort

    Chen and colleagues · Content/publication date: 2023
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original publisher methods/results/limitations inspected; direct PubMed/PMC retrieval failed
    Cited sections: 315 aged 12–20 at four centers; appearance/psychosocial outcomes, variation and two suicide deaths

    Cohort has no randomized untreated comparator. Publisher correction record checked in discovery; 315 count retained. Mental-health care not replaced by treatment.

  7. Masculinising and feminising hormone interventions for adolescents experiencing gender dysphoria or incongruence: a systematic review

    Systematic review

    Taylor and colleagues · Content/publication date: 2024
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original publisher methods/results inspected; direct record/publisher opens failed; original investigators’ institutional abstract and date record also opened
    Cited sections: 53 studies; quality/comparator limits; puberty induction, possible mental-health improvement and limited other outcomes

    Online 9 April 2024; supplement issue 30 October 2024. Search April 2022 with later studies to January 2024 considered. Can overlap Chen cohort; not independent replication.

  8. Interventions to suppress puberty in adolescents experiencing gender dysphoria or incongruence: a systematic review

    Systematic review

    Taylor and colleagues · Content/publication date: 2024
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original publisher outcome/limitation passages inspected; direct publisher retrieval failed; original investigators’ institutional abstract and date record also opened
    Cited sections: 50 studies, limited high-quality evidence, psychological/bone-health uncertainties and subsequent-treatment confounding

    Distinct intervention from hormone review, same review program. Online April 2024, supplement issue October 2024. No blanket reversibility claim.

  9. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study

    Matched observational cohort

    Getahun and colleagues · Content/publication date: 2018
    Accessed: 2026-10-14 UTC · Original indexed abstract and selected original full-report result passages inspected; direct record unavailable
    Cited sections: 2842 transfeminine and 2118 transmasculine participants; VTE association, incomplete exposure capture and generalization limits

    Dated health-system cohort; does not compare every current formulation/route or establish individual causal risk.

  10. Service specification: NHS Children and Young People’s Gender Service

    Current jurisdictional service specification

    NHS England · Content/publication date: 2026
    Accessed: 2026-10-14 UTC · Selected original service-specification PDF passages inspected
    Cited sections: PDF pp1–2, 4 and 10: under-18 scope, holistic care, local services and referral framework

    England-specific current service document. Page retrieval blocked but underlying original PDF opened. No worldwide legal rule or unverified current hormone-prescribing policy stated.

  11. Northern Region Gender Dysphoria Service: Voice and Communication Therapy Information Leaflet

    Official local service patient information

    Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust · Content/publication date: 2024
    Accessed: 2026-10-20 UTC · Complete relevant original HTML and linked eight-page PDF read. Local England service used for definitions and individual goal-setting, not comparative effectiveness, universal eligibility, hormone effects, surgery availability or unsupervised voice exercises. HTML and PDF share PIC/908/0624 June 2024 V1 despite differing website publication/copyright/reference-access dates; one underlying work.
    Cited sections: Original What do we work on, Initial appointment, individual goals and version-control footer; linked PDF pages 2–4 and 8

Scope & review

Population
Transgender and gender-diverse adults; adolescents and prepubertal children explicitly distinguished
Exposure or intervention
Primary care, individualized gender-related treatment discussion, fertility counseling and specialist pathways
Comparison
Adult testosterone immediate versus 3-month wait; youth cohort without randomized untreated comparison; matched vascular cohorts; intervention-specific reviews
Outcomes
Screening needs, fertility/contraception, measured distress/wellbeing, monitoring and vascular associations
Timeframe
Care planning, 3-month trial, 2-year youth follow-up and longer observational follow-up
Jurisdiction
International professional guidance, dated UCSF resources, Australian adult trial, US youth/cohort evidence and England-specific April 2026 youth services; local rules differ

Selected-source educational explanation. Official guidance, original study findings and editorial interpretation are distinguished. No exhaustive search, independent systematic synthesis or qualified medical review has been completed.

Sources checked on their individual access dates. Selected sources were checked; ongoing surveillance and qualified review have separate statuses on the coverage page.

Revision history
  • 2026-10-14 UTC: Added a bounded life-course care guide; qualified clinical, lived-experience and methods review remains pending.
  • 2026-10-20 UTC: Depth19 additive practical-scope expansion after full old/neighbor body audit and selected original-source access; all old section, FAQ and source objects preserved. Qualified review remains pending.

What this article still leaves open

  • Which treatment fits a particular person’s goals and medical circumstances?
  • How do adolescent outcomes vary by age, development, regimen and accompanying care?
  • What are the longer-term benefits and harms of specific hormone preparations and puberty suppression?
  • How can current local access and follow-up arrangements be explained without confusing policy and evidence?
Suggest a correction

Submit a content correction to the editorial queue, or download a local note. Leave out personal medical details. Submitted text is stored privately with a browser receipt session and is visible to this browser and the editor. Clearing cookies removes access to your submission history. This is not an account or a medical service.

Explore the topic map

Browse the health domains connected to this article. The map also identifies topics whose articles remain unwritten.